JP2025517629A5 - - Google Patents

Info

Publication number
JP2025517629A5
JP2025517629A5 JP2024564800A JP2024564800A JP2025517629A5 JP 2025517629 A5 JP2025517629 A5 JP 2025517629A5 JP 2024564800 A JP2024564800 A JP 2024564800A JP 2024564800 A JP2024564800 A JP 2024564800A JP 2025517629 A5 JP2025517629 A5 JP 2025517629A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
compound
tautomer
stereoisomer
enantiomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024564800A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025517629A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2023/092047 external-priority patent/WO2023213271A1/en
Publication of JP2025517629A publication Critical patent/JP2025517629A/ja
Publication of JP2025517629A5 publication Critical patent/JP2025517629A5/ja
Pending legal-status Critical Current

Links

JP2024564800A 2022-05-05 2023-05-04 複素環式化合物、その組成物、及びそれを用いた治療方法 Pending JP2025517629A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2022090877 2022-05-05
CNPCT/CN2022/090877 2022-05-05
PCT/CN2023/092047 WO2023213271A1 (en) 2022-05-05 2023-05-04 Heterocyclic compounds, compositions thereof, and methods of treatment therewith

Publications (2)

Publication Number Publication Date
JP2025517629A JP2025517629A (ja) 2025-06-10
JP2025517629A5 true JP2025517629A5 (enExample) 2026-05-14

Family

ID=88646299

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024564800A Pending JP2025517629A (ja) 2022-05-05 2023-05-04 複素環式化合物、その組成物、及びそれを用いた治療方法

Country Status (5)

Country Link
US (1) US20250066372A1 (enExample)
EP (1) EP4519267A4 (enExample)
JP (1) JP2025517629A (enExample)
CN (1) CN119156389A (enExample)
WO (1) WO2023213271A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025024388A1 (en) 2023-07-21 2025-01-30 Accutar Biotechnology Inc. Aminopyrimidine derivatives as cyclin-dependent kinase inhibitors
WO2025024726A1 (en) * 2023-07-26 2025-01-30 Kinnate Biopharma Inc. Inhibitors of cyclin-dependent kinase
WO2026024674A1 (en) 2024-07-22 2026-01-29 Genesis Therapeutics, Inc. Methods of treating skp2-associated cancers

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7319102B1 (en) * 2003-12-09 2008-01-15 The Procter & Gamble Company Pyrrolo[2,3-d]pyrimidine cytokine inhibitors
UY33227A (es) * 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
CA2954189A1 (en) * 2014-07-26 2016-02-04 Sunshine Lake Pharma Co., Ltd. 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cdk inhibitors and uses thereof
WO2020140052A1 (en) * 2018-12-28 2020-07-02 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
EP3956031A1 (en) * 2019-04-19 2022-02-23 Pfizer Inc. Anti-proliferative agents for treating pah
CN112125911B (zh) * 2020-09-24 2022-08-09 深圳湾实验室坪山生物医药研发转化中心 Cdk9抑制剂及其制备方法与应用

Similar Documents

Publication Publication Date Title
US20230346927A1 (en) COMBINATION of ATR KINASE INHIBITORS and PD-1/PD-L1 INHIBITORS
AU2004289672B2 (en) Inhibition of FGFR3 and treatment of multiple myeloma
US10421761B2 (en) Compounds for kinase modulation, and indications therefor
US10301280B2 (en) Compounds and methods for kinase modulation, and indications therefor
US9771369B2 (en) Compounds and methods for kinase modulation, and indications therefor
JP2006503866A (ja) 癌を処置するための相乗的な方法および組成物
JP2013528204A5 (enExample)
JP2022500402A5 (enExample)
JP2019537571A5 (enExample)
JP2012503018A5 (enExample)
AU2017232610A1 (en) Compounds and methods for kinase modulation and indications therefore
RU2016141934A (ru) Ингибиторы циклин-зависимой киназы 7 (cdk7)
US20140128390A1 (en) Compounds and methods for kinase modulation, and indications therefor
JP2011515462A5 (enExample)
RU2019123319A (ru) Пиразолопиримидины и способы их применения
JP2010523534A5 (enExample)
KR20240035837A (ko) 약화된 이미드 활성을 지닌 btk를 분해하기 위한 이작용성 화합물
TW201333012A (zh) 咪唑并吡咯啶酮化合物
JP2024521818A5 (enExample)
JP2015529194A5 (enExample)
EP3585365A1 (en) Combination of atr kinase inhibitors with parp inhibitors
RU2019125177A (ru) Новые производные амино-имидазопиридина в качестве ингибиторов янус-киназы и их фармацевтическое применение
WO2018153969A1 (en) Combination of atr kinase inhibitors with radium-223 salt
WO2018153971A1 (en) Combination of atr kinase inhibitors
JP2023550902A5 (enExample)